邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

系统性硬化症与肠道菌群的关系

乌日力嘎,  穆荣

downloadPDF
文章导航 > 协和医学杂志  > 2019 >  10(3): 263-267
乌日力嘎, 穆荣. 系统性硬化症与肠道菌群的关系[J]. 协和医学杂志, 2019, 10(3): 263-267. doi: 10.3969/j.issn.1674-9081.2019.03.013
引用本文: 乌日力嘎, 穆荣. 系统性硬化症与肠道菌群的关系[J]. 协和医学杂志, 2019, 10(3): 263-267. doi: 10.3969/j.issn.1674-9081.2019.03.013
shu
Ri-liga WU, Rong MU. Intestinal Microbiota in Systemic Sclerosis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 263-267. doi: 10.3969/j.issn.1674-9081.2019.03.013
Citation: Ri-liga WU, Rong MU. Intestinal Microbiota in Systemic Sclerosis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 263-267. doi: 10.3969/j.issn.1674-9081.2019.03.013
shu

系统性硬化症与肠道菌群的关系

doi: 10.3969/j.issn.1674-9081.2019.03.013

  • 北京大学人民医院风湿免疫科, 北京 100044

基金项目: 

国家自然科学基金面上项目 81471536

国家自然科学基金面上项目 81771706

详细信息
    通讯作者:

    穆荣 电话:010-88326452, E-mail:murongster@163.com

  • 中图分类号: R593.2

Intestinal Microbiota in Systemic Sclerosis

  • Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China

More Information

    摘要
  • 摘要: 肠道菌群对人类健康和疾病有着深远影响。不仅肠道菌群能影响宿主免疫系统发育, 免疫系统本身也能改变肠道菌群。目前发现肠道菌群参与了多种自身免疫性疾病。研究发现, 系统性硬化症(systemic sclerosis, SSc)患者肠道菌群紊乱较常见, 胃肠道易受累, 且其中一些特定菌属与SSc患者胃肠道受累严重程度相关。本文对SSc患者肠道菌群变化特点、肠道菌群与SSc消化系统运动障碍和纤维化的关系以及治疗方案等方面进行系统阐述。
    Abstract: The intestinal microbiota has a profound effect on human health and diseases. It affects the development of the immune system of the host and vice versa. At present, the intestinal microbiota has been found to be involved in many autoimmune diseases. Gastrointestinal tract involvement is common in patients with systemic sclerosis (SSc). Studies found that the gastric and intestinal flora of SSc patients are in disorder, and some of the specific bacteria are related to the severity of gastrointestinal involvement in SSc patients. In this paper, the related research on the intestinal flora of SSc was reviewed, such as changes in intestinal flora, the relationship between the intestinal flora and dyskinesia and fibrosis of the digestive system, and the progress of treatment.
    利益冲突  无
    • HTML全文
    • 参考文献(38)
  • [1] Sallam H, Mcnearney TA, Chen JD. Systematic review:pathophysiology and management of gastrointestinal dysmoti-lity in systemic sclerosis (scleroderma)[J]. Aliment Pharmacol Ther, 2006, 23:691-712. doi:  10.1111/j.1365-2036.2006.02804.x
    [2] Franck-Larsson K, Graf W, Ronnblom A. Lower gastrointestinal symptoms and quality of life in patients with systemic sclerosis:a population-based study[J]. Eur J Gastroenterol Hepatol, 2009, 21:176-182. doi:  10.1097/MEG.0b013e32831dac75
    [3] Bodukam V, Hays RD, Maranian P, et al. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis[J]. Rheumatology (Oxford), 2011, 50:330-334. doi:  10.1093/rheumatology/keq296
    [4] Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system[J]. Science, 2012, 336:1268-1273. doi:  10.1126/science.1223490
    [5] Yamashiro Y. Gut Microbiota in Health and Disease[J]. Ann Nutr Metab, 2017, 71:242-246. doi:  10.1159/000481627
    [6] Chiller K, Selkin BA, Murakawa GJ. Skin microflora and bacterial infections of the skin[J]. J Investig Dermatol Symp Proc, 2001, 6:170-174. https://www.sciencedirect.com/science/article/pii/S0022202X15529011
    [7] Andreasson K, Alrawi Z, Persson A, et al. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease[J]. Arthritis Res Ther, 2016, 18:278. doi:  10.1186/s13075-016-1182-z
    [8] Dominguez-bello MG, De Jesus-Laboy KM, Shen N, et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer[J]. Nat Med, 2016, 22:250-253. doi:  10.1038/nm.4039
    [9] Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns[J]. Proc Natl Acad Sci U S A, 2010, 107:11971-11975. doi:  10.1073/pnas.1002601107
    [10] Mariat D, Firmesse O, Levenez F, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age[J]. BMC Microbiol, 2009, 9:123. doi:  10.1186/1471-2180-9-123
    [11] Mazmanian SK, Liu CH, Tzianabos AO, et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system[J]. Cell, 2005, 122:107-118. doi:  10.1016/j.cell.2005.05.007
    [12] Smith K, Mccoy KD, Macpherson AJ. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota[J]. Semin Immunol, 2007, 19:59-69. doi:  10.1016/j.smim.2006.10.002
    [13] An D, Oh SF, Olszak T, et al. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells[J]. Cell, 2014, 156:123-133. doi:  10.1016/j.cell.2013.11.042
    [14] Mukherji A, Kobiita A, Ye T, et al. Homeostasis in intestinal epithelium is orchestrated by the circadian clock and micro-biota cues transduced by TLRs[J]. Cell, 2013, 153:812-827. doi:  10.1016/j.cell.2013.04.020
    [15] Round JL, Lee SM, Li J, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota[J]. Science, 2011, 332:974-977. doi:  10.1126/science.1206095
    [16] Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells[J]. Immunity, 2010, 32:815-827. doi:  10.1016/j.immuni.2010.06.001
    [17] Jangi S, Gandhi R, Cox LM, et al. Alterations of the human gut microbiome in multiple sclerosis[J]. Nat Commun, 2016, 7:12015. doi:  10.1038/ncomms12015
    [18] Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system[J]. Cell, 2007, 131:33-45. doi:  10.1016/j.cell.2007.08.017
    [19] Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis[J]. Elife, 2013, 2:01202. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM24192039
    [20] Alekseyenko AV, Perez-Perez GI, De Souza A, et al. Community differentiation of the cutaneous microbiota in psoriasis[J]. Microbiome, 2013, 1:31. doi:  10.1186/2049-2618-1-31
    [21] Lopez P, De Paz B, Rodriguez-Carrio J, et al. Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients[J]. Sci Rep, 2016, 6:24072. doi:  10.1038/srep24072
    [22] Volkmann ER, Chang YL, Barroso N, et al. Association of Systemic Sclerosis With a Unique Colonic Microbial Consor-tium[J]. Arthritis Rheumatol, 2016, 68:1483-1492. doi:  10.1002/art.39572
    [23] Volkmann ER, Hoffmann-Vold AM, Chang YL, et al. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts.[J]. BMJ Open Gastroenterol, 2017, 4:e000134. doi:  10.1136/bmjgast-2017-000134
    [24] Volkmann ER. Intestinal microbiome in scleroderma:recent progress[J]. Curr Opin Rheumatol, 2017, 29:553-560. https://pubmed.ncbi.nlm.nih.gov/28719392/
    [25] Marie I, Ducrotte P, Denis P, et al. Small intestinal bacterial overgrowth in systemic sclerosis[J]. Rheumatology (Oxford), 2009, 48:1314-1319. doi:  10.1093/rheumatology/kep226
    [26] Khanna D, Hays RD, Maranian P, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument[J]. Arthritis Rheum, 2009, 61:1257-1263. doi:  10.1002/art.24730
    [27] Shah SC, Day LW, Somsouk M, et al. Meta-analysis:antibiotic therapy for small intestinal bacterial overgrowth[J]. Aliment Pharmacol Ther, 2013, 38:925-934. doi:  10.1111/apt.12479
    [28] Mehta H, Goulet PO, Mashiko S, et al. Early-Life Antibiotic Exposure Causes Intestinal Dysbiosis and Exacerbates Skin and Lung Pathology in Experimental Systemic Sclerosis[J]. J Invest Dermatol, 2017, 137:2316-2325. doi:  10.1016/j.jid.2017.06.019
    [29] Mazagova M, Wang L, Anfora AT, et al. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice[J]. Faseb J, 2015, 29:1043-1055. doi:  10.1096/fj.14-259515
    [30] Park JS, Choi JW, Jhun J, et al. Lactobacillus acidophilus Improves Intestinal Inflammation in an Acute Colitis Mouse Model by Regulation of Th17 and Treg Cell Balance and Fibrosis Development[J]. J Med Food, 2018, 21:215-224. doi:  10.1089/jmf.2017.3990
    [31] Bennet SMP, Böhn L, Störsrud S, et al.Multivariate modelling of faecal bacterial profiles of patients with IBS pridicts responsiveness to a diet low in FODMAPs[J]. Gut, 2018, 67:872-882. doi:  10.1136/gutjnl-2016-313128
    [32] Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity[J]. Science, 2016, 352:565-569. doi:  10.1126/science.aad3369
    [33] Lewis JD, Chen EZ, Baldassano RN, et al. Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease[J]. Cell Host Microbe, 2015, 18:489-500. doi:  10.1016/j.chom.2015.09.008
    [34] Frech TM, Khanna D, Maranian P, et al. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating distention[J]. Clin Exp Rheumatol, 2011, 29:S22-S25. https://pubmed.ncbi.nlm.nih.gov/21586214/
    [35] Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease[J]. BMC Gastroenterol, 2004, 4:5. doi:  10.1186/1471-230X-4-5
    [36] 中国医师协会检验医师分会感染性疾病检验医学专家委员会.中国成人艰难梭菌感染诊断和治疗专家共识[J].协和医学杂志, 2017, 8:131-138. http://www.cnki.com.cn/Article/CJFDTotal-XHYX2017Z1011.htm
    [37] Moayyedi P. Fecal transplantation:any real hope for inflammatory bowel disease?[J]. Curr Opin Gastroenterol, 2016, 32:282-286. doi:  10.1097/MOG.0000000000000285
    [38] Allegretti JR, Hamilton MJ. Restoring the gut microbiome for the treatment of inflammatory bowel diseases[J]. World J Gastroenterol, 2014, 20:3468-3474. doi:  10.3748/wjg.v20.i13.3468
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  337
  • HTML全文浏览量:  58
  • PDF下载量:  18
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-01-23
  • 刊出日期:  2020-09-18

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！